Navigation Links
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
Date:5/6/2008

- Product Revenue Increased 78 Percent Compared to First Quarter of 2007 - - Tests Delivered Grew 68 Percent Compared to First Quarter of 2007 -

- Conference Call Today at 4:30 p.m. ET -

REDWOOD CITY, Calif., May 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2008.

Total revenue increased to $23.4 million in the first quarter of 2008 compared to $14.1 million in the first quarter of 2007. Product revenue from Oncotype DX was $23.3 million in the first quarter of 2008, an increase of 78 percent compared to $13.1 million in the first quarter of 2007, reflecting continued growth in adoption and reimbursement. Contract revenue comprised the balance of total revenue for the first quarters of 2008 and 2007.

"We are seeing the positive effects of inclusion in ASCO and NCCN treatment guidelines, and additional rigorous clinical studies of our Oncotype DX breast cancer assay. We believe these factors, as well as our ongoing commercial efforts, contributed to substantial increases in adoption, continued positive reimbursement policies, and strong product revenue growth in the first quarter of 2008," said Randy Scott, Ph.D., Chairman and Chief Executive Officer of Genomic Health. "We believe that physicians are increasingly incorporating Oncotype DX into standard practice for breast cancer treatment."

Additional First Quarter 2008 Financial Results

During the first quarter of 2008, approximately 50 percent of product revenue was recorded on an accrual basis and recognized at the time the test results were delivered, reflecting established payment patterns from payors with coverage policies and
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and ... solutions for developers of biosimilars at the 2013 ... Sheraton San Diego Hotel and Marina ... will have the opportunity to speak with company representatives ... Paths That Cross" on May 21 from 1-2 p.m. ...
(Date:5/20/2013)... 20, 2013 Cempra, Inc. (Nasdaq: CEMP), ... antibiotics to meet critical medical needs in the ... presented data at the American Thoracic Society International ... demonstrating the antibacterial and enhanced immunomodulatory activity ... 2 clinical trial in outpatients with community acquired ...
(Date:5/20/2013)... Pittsburgh, PA (PRWEB) May 20, 2013 ... the Allegheny General Hospital (AGH) Cardiovascular Institute ... of coronary artery disease (CAD) over the ... procedures such as balloon angioplasty and coronary artery stent ... will once again play a prominent role in the ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
... Filed With the FDA for the Fourth Genmab Antibody ... the Company,s Collaboration with Roche., COPENHAGEN, December 12 ... New Drug application (IND) for a,Genmab antibody developed under ... FDA by Roche. Genentech and Roche are collaborating on,development ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Dec. ... leading developer in the treatment of multiple sclerosis ... Board (DSMB) has,reviewed data from the Company,s on-going ... for the treatment of secondary progressive MS and,recommended ...
Cached Biology Technology:Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... post doctoral fellow Virginie Mieulet, in the Faculty of Medicine ... is so vital in fighting infection. , They have discovered ... body know that it,s being attacked by an infection. , ... could have implications for the millions of people in third ...
... Trypanosomes are parasites responsible for many human and ... parasites cause, African sleeping sickness, results from the bite ... at risk in 36 sub-Saharan countries. The recent 1998-2001 ... of Congo and Uganda killed tens of thousands of ...
... A team led by Massachusetts General Hospital (MGH) scientists ... accurately isolating neutrophils the most abundant type of ... accomplishment that could provide information essential to better understanding ... system, described in a Nature Medicine paper ...
Cached Biology News:New research shows how disease-causing parasite gets around human innate immunity 2New research shows how disease-causing parasite gets around human innate immunity 3New research shows how disease-causing parasite gets around human innate immunity 4Microfluidic device allows collection, analysis of hard-to-handle immune cells 2
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: